Moleculin Completes Dosing In Part A Of Pivotal MIRACLE Trial; Data Readout Expected In Q1 2027

(RTTNews) - Moleculin Biotech, Inc. (MBRX) announced that it has completed patient dosing in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for adults with relapsed or refractory acute myeloid leukemia (R/R AML).